WordNet

not moving quickly; taking a comparatively long time; "a slow walker"; "the slow lane of traffic"; "her steps were slow"; "he was slow in reacting to the news"; "slow but steady growth"
cause to proceed more slowly; "The illness slowed him down" (同)slow down, slow up
become slow or slower; "Production slowed" (同)slow down, slow up, slack, slacken
(used of timepieces) indicating a time earlier than the correct time; "the clock is slow"
at a slow tempo; "the band played a slow waltz"
use recreational drugs (同)do drugs
administer a drug to; "They drugged the kidnapped tourist" (同)dose
a substance that is used as a medicine or narcotic
the performance of a part or role in a drama (同)playing, playacting, performing
serving temporarily especially as a substitute; "the acting president"
one of the proteins into which actomyosin can be split; can exist in either a globular or a fibrous form

PrepTutorEJDIC

(速度・動作などが)『遅い』,のろい / 《補語または名詞の後にのみ用いて》(時計などが)『遅れている』 / 『ゆったりした』,あわてない / (人が)理解の遅い,頭の鈍い / (生活・パーティーなどが)『活気のない』,おもしろくない / 遅く,ゆっくり(slowly) / 『遅くなる』,速度を落とす《+『down』(『up』)》 / …‘を'『遅くする』,‘の'速度を落とす《+『名』+『down』(『up』),+『down』(『up』)+『名』》
『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる
代理の,臨時の / 演出用の / 演出,演技
純蛋白質(筋肉生成に役立つ)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. リウマチ性疾患における免疫抑制剤および疾患修飾剤の使用の概要 overview of the use of immunosuppressive and disease modifying drugs in the rheumatic diseases
2. 患者情報：疾患修飾抗リウマチ薬（DMARDs）（詳細） disease modifying antirheumatic drugs dmards beyond the basics
3. 成人における初回の抗リウマチ薬（DMARD）治療に抵抗性の活動性関節リウマチに対
する治療 treatment of rheumatoid arthritis resistant to initial dmard therapy in adults
4. 成人における中等度～重度の活動性関節リウマチの初期治療 initial treatment of moderately to severely active rheumatoid arthritis in adults
5. 成人における関節リウマチのマネージメントの一般的原則 general principles of management of rheumatoid arthritis in adults

English Journal

Treatment of juvenile rheumatoid arthritis.

Kim KN.SourceDepartment of Pediatrics, Hangang Sacred Heart Hospital, School of Medicine Hallym University, Seoul, Korea.
Korean journal of pediatrics.Korean J Pediatr.2010 Nov;53(11):936-41. Epub 2010 Nov 30.
The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory dr
PMID 21218015

Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.

[No authors listed]Abstract(1) First-line disease-modifying treatment for rheumatoid arthritis is based on "slow-acting" antirheumatic agents, generally methotrexate. Subsequent options include a TNF-alpha antagonist, followed by rituximab or possibly abatacept; (2) Tocilizumab, a monoclonal antibody, inhibits interleukin-6 receptors. It is licensed in the European Union for patients with rheumatoid arthritis in whom other drugs have failed; (3) Clinical evaluation includes 4 placebo-controlled trials of the methotrexate-tocilizumab combination, after failure of a slow-acting antirheumatic drug (3 trials) or failure of a slow-acting antirheumatic drug and a TNF-alpha antagonist (1 trial). An indirect comparison suggests that tocilizumab is no more effective than rituximab in patients with multiple treatment failure; (4) Tocilizumab, like TNF-alpha antagonists, is an immunosuppressant. It carries a risk of serious infections, haematological disorders (neutropenia, thrombocytopenia), gastrointestinal bleeding, hepatic disorders, and systemic and local reactions during the infusion; (5) the adverse effects of long-term tocilizumab therapy are unknown, particularly the risk of cancer; (6) Tocilizumab carries a risk of interactions with drugs that are metabolised by cytochrome P450 isoenzymes. Clinical consequences cannot be ruled out when co-administered drugs have a narrow therapeutic margin; (7) Tocilizumab is administered intravenously every 4 weeks, making it slightly more convenient that rituximab at the beginning of treatment; (8) In patients with rheumatoid arthritis and multiple treatment failure, it remains to be shown whether tocilizumab has a better risk-benefit balance than rituximab, a drug with which we have more experience. It is therefore better to continue to use rituximab, or possibly abatacept.
Prescrire international.Prescrire Int.2009 Oct;18(103):198-201.
(1) First-line disease-modifying treatment for rheumatoid arthritis is based on "slow-acting" antirheumatic agents, generally methotrexate. Subsequent options include a TNF-alpha antagonist, followed by rituximab or possibly abatacept; (2) Tocilizumab, a monoclonal antibody, inhibits interleukin-6 r
PMID 19882783

Japanese Journal

A 15-year follow-up study on the outcome in patients with early rheumatoid arthritis

MIYAGI KENICHI,AZUMA TAKESHI,NAITOH AKIFUMI,SAKAIDA HIROYUKI,SAKATA MOROMICHI,NAKAGAWA TAKEMASA,MIYAHARA HIDEO,SHIRATAKA MASUO
Japanese journal of rheumatology 8(2), 117-129, 1998-06-01
NAID 10016289862